Silicon Investor - Bottom Fish Stocks (Between .05 and $5)

[DJK1] $IDEX - Ideanomics Stock is a Low-Priced EV Play for Speculators marketbeat.c...

DJK1 — 2/23/2021 10:39:29 AM

$IDEX - Ideanomics Stock is a Low-Priced EV Play for Speculators

marketbeat.com

[Postman] ili.v at .08 cents is at a bottom imo.

Postman — 2/9/2021 6:04:21 AM

[DJK1] $IDEX - Appears $5 is the next level. [graphic]

DJK1 — 2/3/2021 1:49:31 PM

$IDEX - Appears $5 is the next level.

[Catfish] Thanks Dan. I still post up the PRs daily over on the I-Hub Bottom Fish board. ...

Catfish — 5/15/2019 8:26:40 AM

Thanks Dan. I still post up the PRs daily over on the I-Hub Bottom Fish board. I may still post up something here from time to time.

[dan6] Thanks for all your posting over the years! -dan

dan6 — 4/30/2019 10:36:51 AM

[Catfish] I am still posting up PRs, but on this site only: investorshub.advfn.com

Catfish — 4/25/2019 8:49:46 AM

[Catfish] SLS - 1.03 Pre-market now at 1.05/1.07 Alliance Global Partners Initiates Cov...

Catfish — 4/8/2019 8:23:27 AM

SLS - 1.03 Pre-market now at 1.05/1.07

Alliance Global Partners Initiates Coverage On SELLAS Life Sciences with Buy Rating, Announces $4.50 Price Target

tradescores.com

[Catfish] APDN - .683 Pre-market now at .71/.78 Applied DNA Subsidiary LineaRx Achieves...

Catfish — 4/8/2019 8:22:58 AM

APDN - .683 Pre-market now at .71/.78

Applied DNA Subsidiary LineaRx Achieves Biotech Industry First with Anti-CD19 Expression in Human CAR T Cells via Proprietary Non-Viral, Plasmid-Free Platform

tradescores.com

[Catfish] SCYX - 1.63 Pre-market now at 1.81/1.85 The Week Ahead In Biotech: Conference...

Catfish — 4/8/2019 7:53:21 AM

SCYX - 1.63 Pre-market now at 1.81/1.85

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

SCYNEXIS Reports Its Ibrexafungerp Showed Favorable Clinical Activity In Resistance Fungal Infections In Data Presented At ECCMID

tradescores.com

[Catfish] VLRX - .2958 Pre-market now at .3603/.3899 Valeritas Reports V-Go Wearable In...

Catfish — 4/8/2019 7:47:51 AM

VLRX - .2958 Pre-market now at .3603/.3899

Valeritas Reports V-Go Wearable Insulin Delivery Device Showed 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment

tradescores.com

[Catfish] SFET - 2.50 Pre-market now at 2.80/2.81 Safe-T Awarded Patent in Israel Cover...

Catfish — 4/8/2019 7:44:36 AM

SFET - 2.50 Pre-market now at 2.80/2.81

Safe-T Awarded Patent in Israel Covering its Reverse Access Technology

tradescores.com

[Catfish] NBEV - 4.785 Pre-market now at 5.36/5.39 New Age Beverages Expands Marley Bra...

Catfish — 4/8/2019 7:41:44 AM

NBEV - 4.785 Pre-market now at 5.36/5.39

New Age Beverages Expands Marley Brand Partnership With Walmart -- Shares Up More Than 9%

tradescores.com

[Catfish] HSGX - .1109 Pre-market now at .2307/.248 Histogenics and Ocugen Enter into D...

Catfish — 4/8/2019 7:39:55 AM

HSGX - .1109 Pre-market now at .2307/.248

Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

tradescores.com

[Catfish] TROV - 3.60 Pre-market now at 4.15/4.20 BZ: UPDATE: Trovagene Reports '~90% c...

Catfish — 4/5/2019 8:25:38 AM

TROV - 3.60 Pre-market now at 4.15/4.20

BZ: UPDATE: Trovagene Reports '~90% clinical benefit acheived - complete response + partial response + stable disease'

tradescores.com

[Catfish] VTL - .2091 Pre-market now at .251/.26 Vital Therapies, Inc. Announces Stockh...

Catfish — 4/5/2019 7:54:42 AM

VTL - .2091 Pre-market now at .251/.26

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG

tradescores.com

[Catfish] PAVM - 1.26 Conference call to be held on April 4, 2019 at 4:30 p.m. Easte...

Catfish — 4/4/2019 9:46:52 AM

PAVM - 1.26

Conference call to be held on April 4, 2019 at 4:30 p.m. Eastern time

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update.

MANAGEMENT COMMENTARY

“I am very pleased with the progress PAVmed has made during what has been a very active and productive fourth quarter of 2018 and in recent months,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We have achieved several important milestones across our lead product pipeline and are poised to complete several more in this quarter.”

Highlights

Refinanced senior secured debt under favorable terms, including a lower coupon rate and no attached warrants, strengthening our balance sheet by removing the July 2019 debt maturity overhang and increasing our working capital runway;Reached a consensus with the FDA on the parameters of the CarpX™ minimally-invasive carpal tunnel device’s first-in-human (FIH) safety study and completed the complex logistics necessary to initiate and complete the treatment phase of the study in Christchurch, New Zealand in the coming weeks;Completed the EsoGuard™ (formerly EsoCheck™ Dx) methylated DNA biomarker diagnostic test’s Laboratory Developed Test (LDT) validation process and filed for a Proprietary Laboratory Analysis (PLA) diagnostic CPT billing code through the American Medical Association, which is the first step in securing Medicare reimbursement;Completed the EsoCheck™ esophageal cell collection device’s GLP animal study as well as additional manufacturing verifications requested by FDA to support its 510(k) pathway regulatory clearance;Launched a world-class Lucid Diagnostics medical advisory board consisting of internationally renowned experts in gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE) and esophageal cancer, with specific expertise and experience in developing the current published society guidelines on the management of BE;Appointed a veteran life sciences industry executive with extensive experience in the development and execution of clinical and regulatory strategy, including sophisticated clinical trials, as Lucid’s Chief Medical Officer;Completed the PortIO™ implantable intraosseous vascular access device’s GLP animal study, requested by the FDA to support its de novo pathway regulatory clearance;Completed a PortIO pilot animal study demonstrating an unprecedented maintenance-free implant duration of over 60 days, which a former president of the Society of Interventional Radiology described as a “truly groundbreaking accomplishment” which would represent “one of the most important advances in long-term vascular access”;Completed a series of bench-top tests of the NextFlo™ Infusion System demonstrating flow accuracy comparable to expensive electronic infusion pumps, independent of intravenous (IV) bag height, which a leading critical care physician described as a breakthrough which would “revolutionize how we deliver infusions to patients while significantly lowering costs”.CarpX

CarpX is a minimally invasive device designed to treat carpal tunnel syndrome, which PAVmed believes will dramatically reduce recovery times compared to traditional open surgery and target an estimated immediately addressable domestic market opportunity of over $1 billion.

PAVmed has been working closely with the FDA to secure its U.S. 510(k) regulatory clearance of CarpX. During a pre-submission meeting earlier this year, the FDA recommended clinical testing to definitively document procedural safety in humans and indicated that data from a clinical study outside of the U.S. would be acceptable, precluding the need to engage in the FDA’s time-consuming IDE process required for U.S. studies. PAVmed offered to amend its previously planned FIH clinical trial ( ClinicalTrials.gov Identifier: NCT03747510) in Christchurch, New Zealand to meet this clinical testing recommendation and postponed the initiation of the study until study parameters were finalized with the FDA and local logistical matters could be finalized.

Following multiple discussions, PAVmed reached a consensus with the FDA on the parameters of the study – a single-arm, two-center, two-surgeon, 20-patient study of the CarpX procedure in carpal tunnel syndrome patients, with a device safety primary endpoint over a limited 90-day follow-up period. Final logistical matters led to a brief delay in the initiation of the study which was exacerbated by a temporary freeze on all elective surgeries following the tragic events in Christchurch last month. These logistical matters have now been addressed and the elective surgery freeze has been lifted, allowing treatment to be initiated and completed in the coming weeks.

EsoGuard/EsoCheck

The EsoGuard (formerly EsoCheck Dx) DNA biomarker diagnostic test and the EsoCheck device, which collect cells from a targeted region of the esophagus in a five-minute office-based procedure, are revolutionary technologies licensed by PAVmed’s majority-owned subsidiary, Lucid Diagnostics Inc. (“Lucid”). Lucid decided to rename the diagnostic test EsoGuard to better distinguish it from the EsoCheck cell collection device since each technology has promising applications that are independent of the other. This change will be formally introduced at the major upcoming gastroenterology meeting, Digestive Diseases Week (DDW), where Lucid will have a strong presence including exhibits and presentations. Lucid is pursuing a two-phase regulatory and commercialization strategy which seeks to maximize the technologies’ long-term commercial opportunity while providing near-term value-inflection commercial milestones.

EsoGuard is a methylated DNA biomarker diagnostic test which has been shown in a published human study to be highly accurate at detecting Barrett’s Esophagus (BE), a pre-cursor to highly lethal esophageal cancer in patients with chronic heart burn or acid reflux (GERD). Lucid believes that the EsoGuard diagnostic test, when performed on samples collected by EsoCheck, has the potential to save many lives through early BE detection. The estimated immediately addressable domestic market opportunity for EsoGuard is at least $2 billion based on tens of millions of U.S. GERD patients who are BE screening candidates according to published guidelines.

The EsoGuard Laboratory Developed Test (LDT) validation process has been completed at the central reference laboratory in Cleveland. This week the American Medical Association (AMA) confirmed receipt of Lucid’s application for a Proprietary Laboratory Analysis (PLA) diagnostic CPT billing code for EsoGuard. This is the first step towards securing Medicare and subsequently private payor reimbursement for the diagnostic test.

[Catfish] ADOM - .3161 Pre-market now at .33/.35 ADOMANI's Backlog Grows to $12.9M, a 2...

Catfish — 4/4/2019 9:12:45 AM

ADOM - .3161 Pre-market now at .33/.35

ADOMANI's Backlog Grows to $12.9M, a 28% Increase from its Backlog Announced February 12, 2019

tradescores.com

[Catfish] TEUM - 4.89 Pre-market now at 5.15/5.17 Pareteum Says It Booked Record $100 M...

Catfish — 4/4/2019 8:41:13 AM

TEUM - 4.89 Pre-market now at 5.15/5.17

Pareteum Says It Booked Record $100 Mln of Orders in March

tradescores.com

[Catfish] SLS - 1.01 Pre-market now at 1.12/1.14 SELLAS Life Sciences Group and World-R...

Catfish — 4/4/2019 8:39:05 AM

SLS - 1.01 Pre-market now at 1.12/1.14

SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)

tradescores.com

[Catfish] BLDP - 3.09 Pre-market now at 3.12/3.20 Ballard to Establish Fuel Cell Center...

Catfish — 4/4/2019 8:05:23 AM

BLDP - 3.09 Pre-market now at 3.12/3.20

Ballard to Establish Fuel Cell Center of Excellence in Europe to Serve Marine Market with Zero-Emission Solutions

tradescores.com

[Catfish] MYOS - 1.48 Pre-market now at 1.76/1.78 MYOS RENS Technology Signs Distributi...

Catfish — 4/4/2019 8:00:36 AM

MYOS - 1.48 Pre-market now at 1.76/1.78

MYOS RENS Technology Signs Distribution Agreement with National Sales Associates, LLC

tradescores.com

[Catfish] PTN - .9835 Pre-market now at 1.07/1.08 Palatin Technologies Announces Positi...

Catfish — 4/4/2019 7:56:03 AM

PTN - .9835 Pre-market now at 1.07/1.08

Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel
Diseases

tradescores.com

[Catfish] TNXP - 2.33 Pre-market now at 2.96/2.98 Tonix Pharmaceuticals Plans to Expand...

Catfish — 4/4/2019 7:52:23 AM

TNXP - 2.33 Pre-market now at 2.96/2.98

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

tradescores.com

[Catfish] OPTT - Over $8 and it hit $10.40 this AM on this news. Ocean Power Technologi...

Catfish — 4/3/2019 9:38:57 AM

OPTT - Over $8 and it hit $10.40 this AM on this news.

Ocean Power Technologies Up 96%; To Study Use of Products in Subsea Wells >OPTT

[Catfish] SCYX - 1.55 Pre-market now at 1.57/1.65 SCYNEXIS's Ibrexafungerp Shows Favora...

Catfish — 4/3/2019 8:42:40 AM

SCYX - 1.55 Pre-market now at 1.57/1.65

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

tradescores.com

[Catfish] OESX - .96 Pre-market now at 1.00/1.16 Orion Secures Additional $35 Million L...

Catfish — 4/3/2019 8:39:56 AM

OESX - .96 Pre-market now at 1.00/1.16

Orion Secures Additional $35 Million LED Lighting Installation Contract

tradescores.com

[Catfish] CHFS - 4.55 Pre-market now at 4.75/4.80 BZ: Capstone Reports Order For Two C2...

Catfish — 4/3/2019 8:37:45 AM

CHFS - 4.55 Pre-market now at 4.75/4.80

BZ: Capstone Reports Order For Two C200 Systems From Global Biotech Company To Increase Operational Efficiency With CCHP Adoption

CHF Solutions Submits Patent Application for Pediatric Use of Aquadex FlexFlow® System

tradescores.com

[Catfish] APTX - 4.10 Pre-market now at 5.07/5.08 Data in Parkinson’s Disease Model in ...

Catfish — 4/3/2019 8:07:07 AM

APTX - 4.10 Pre-market now at 5.07/5.08

Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458

tradescores.com

[Catfish] PRPO - .1264 Pre-market now at .14/.146 Precipio’s HemeScreen™ Adopted by Met...

Catfish — 4/3/2019 7:40:51 AM

PRPO - .1264 Pre-market now at .14/.146

Precipio’s HemeScreen™ Adopted by Methodist Health

tradescores.com

[Catfish] TEUM - 4.54 Pre-market now at 4.63/4.67 Pareteum Wins $22 Million Contract wi...

Catfish — 4/2/2019 8:17:58 AM

TEUM - 4.54 Pre-market now at 4.63/4.67

Pareteum Wins $22 Million Contract with Digital Currency Wi-Fi Provider

tradescores.com

[Catfish] ONCS - .614 Pre-market now at .65/.68 OncoSec Presents Promising Preclinical ...

Catfish — 4/2/2019 8:14:11 AM

ONCS - .614 Pre-market now at .65/.68

OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

tradescores.com

[Catfish] LPTX - 1.95 Pre-market now at 2.07/2.08 Leap Therapeutics Reports Clinical Up...

Catfish — 4/2/2019 8:02:56 AM

LPTX - 1.95 Pre-market now at 2.07/2.08

Leap Therapeutics Reports Clinical Update and 2018 Financial Results

tradescores.com

[Catfish] MLSS - .36012 Pre-market now at .3825/.395 Milestone Scientific Q4 EPS $0.01 ...

Catfish — 4/2/2019 8:00:19 AM

MLSS - .36012 Pre-market now at .3825/.395

Milestone Scientific Q4 EPS $0.01 Up From $(0.06) YoY, Sales $3.766M Beat $2.05M Estimate

tradescores.com

[Catfish] NNDM - .7158 Pre-market now at .79/.82 Top Ten Defense and Aviation Multinati...

Catfish — 4/2/2019 7:52:39 AM

NNDM - .7158 Pre-market now at .79/.82

Top Ten Defense and Aviation Multinational Buys Nano Dimension System for Additive Manufacturing of Electronics

Nano Dimension 3D Prints Side-Mounting Technology onto Circuit Boards

tradescores.com

[Catfish] SFET - 2.48 Pre-market now at 3.00/3.08 Safe-T Identified as a Single Vendor ...

Catfish — 4/2/2019 7:49:47 AM

SFET - 2.48 Pre-market now at 3.00/3.08

Safe-T Identified as a Single Vendor and Receives an Order from a Government Ministry in Israel

tradescores.com

[Catfish] NIO - 5.21 Pre-market now at 5.38/5.39 NIO Delivered 3,989 ES8 Vehicles in Q1...

Catfish — 4/2/2019 7:47:07 AM

NIO - 5.21 Pre-market now at 5.38/5.39

NIO Delivered 3,989 ES8 Vehicles in Q1 2019

tradescores.com

[Catfish] ADMA - 4.07 Pre-market now at 6.64/6.65 FDA Approves ASCENIV™, a Novel Intrav...

Catfish — 4/2/2019 7:44:07 AM

ADMA - 4.07 Pre-market now at 6.64/6.65

FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

ADMA Biologics Looks To Commercially Launch Asceniv In H2 After FDA Approval

tradescores.com

[Catfish] AVEO - 1.38 Up .56 for the day, but news out after the close should have this on...

Catfish — 4/2/2019 7:40:42 AM

AVEO - 1.38 Up .56 for the day, but news out after the close should have this on the launch for Tuesday. Glad I still have a few shares.

AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML

tradescores.com

[Catfish] PULM - 1.27 Pre-market now at 1.60/1.65 Pulmatrix Enters Into Binding Term Sh...

Catfish — 4/1/2019 9:03:32 AM

PULM - 1.27 Pre-market now at 1.60/1.65

Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole

tradescores.com

[Catfish] ONCS - .557 Pre-market now at .57/.63 OncoSec Announces Advanced Therapy Medi...

Catfish — 4/1/2019 8:16:25 AM

ONCS - .557 Pre-market now at .57/.63

OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma

tradescores.com

[Catfish] ZIOP - 3.85 Pre-market now at 4.10/4.20 Ziopharm Oncology Announces FDA Fast ...

Catfish — 4/1/2019 8:13:53 AM

ZIOP - 3.85 Pre-market now at 4.10/4.20

Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma

tradescores.com

[Catfish] MNKD - 1.97 Pre-market now at 2.04/2.08 MannKind Receives $12.5 Million Miles...

Catfish — 4/1/2019 8:11:53 AM

MNKD - 1.97 Pre-market now at 2.04/2.08

MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

tradescores.com

[Catfish] CYTX - .259 Pre-market now at .25/.28 Cytori Therapeutics Q4 EPS $0.11 Beats ...

Catfish — 4/1/2019 8:09:16 AM

CYTX - .259 Pre-market now at .25/.28

Cytori Therapeutics Q4 EPS $0.11 Beats $(0.30) Estimate, Sales $1.422M Miss $1.89M Estimate

tradescores.com

[Catfish] ADXS - 5.91 Pre-market now at 6.71/7.10 ADXS-PSA in Combination with KEYTRUDA...

Catfish — 4/1/2019 8:06:26 AM

ADXS - 5.91 Pre-market now at 6.71/7.10

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

tradescores.com

[Catfish] VKTX - 9.94 Pre-market now at 10.32/10.32 ....news out on 3/29 Viking Therape...

Catfish — 4/1/2019 8:04:05 AM

VKTX - 9.94 Pre-market now at 10.32/10.32 ....news out on 3/29

Viking Therapeutics Shares Jump As Analysts See Drug Trial Positives

tradescores.com

[Catfish] CYCC - .935 Pre-market now at .94/.96 Cyclacel Announces Presentation of Phas...

Catfish — 4/1/2019 8:00:56 AM

CYCC - .935 Pre-market now at .94/.96

Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

tradescores.com

[Catfish] FRSX - 1.3499 Pre-market now at 1.42/1.43 Foresight Receives Notice of Allowa...

Catfish — 4/1/2019 7:58:57 AM

FRSX - 1.3499 Pre-market now at 1.42/1.43

Foresight Receives Notice of Allowance for First Patent Application from USPTO for "Running Vehicle Alerting System and Method"

tradescores.com

[Catfish] SELB - 2.37 Pre-market now at 2.71/2.74 BZ: Selecta Biosciences Shares Rise 1...

Catfish — 4/1/2019 7:58:34 AM

SELB - 2.37 Pre-market now at 2.71/2.74

BZ: Selecta Biosciences Shares Rise 14% Premarket; Co Director Timothy Springer Purchased 4M Shares @$1.50/Share Reported in a Form 4 Filing on
Friday

tradescores.com

[Catfish] AMRS - 2.10 Pre-market now at 2.60/2.69 Amyris Delivers on First CBD Mileston...

Catfish — 3/29/2019 8:36:55 AM

AMRS - 2.10 Pre-market now at 2.60/2.69

Amyris Delivers on First CBD Milestone; Earns $10 Million

tradescores.com

[Catfish] RENN - 1.65 Pre-market now at 1.70/1.78 BZ: Renren Inc. Q3 Earnings $(0.42)/A...

Catfish — 3/29/2019 8:34:45 AM

RENN - 1.65 Pre-market now at 1.70/1.78

BZ: Renren Inc. Q3 Earnings $(0.42)/ADS, Sales $116.844M Up From $61.763M YoY

tradescores.com